rs1252749: Understanding Genetic Associations with Sleep Medication
The genetic variant rs1252749 is a common single nucleotide polymorphism (SNP) located in an intergenic region of the human genome. It has been identified in large-scale genome-wide association studies (GWAS) as a lead variant associated with the purchase of sleep medications.
What each genotype means
Baseline sleep medication association
This genotype represents the common baseline state for this genetic variant. Large-scale genome-wide association studies have identified this variant as a marker associated with sleep medication purchases, though the specific biological mechanism remains under investigation. Please discuss any concerns regarding sleep quality or medication use with your clinician or pharmacist.
This is a common genotype found across diverse global populations.
Associated with sleep medication use
Carrying one copy of the G allele has been statistically associated with an increased likelihood of sleep medication purchases in large-scale population studies. This association is considered a proxy for underlying sleep-related traits or patterns rather than a direct diagnostic indicator. Please discuss any sleep-related concerns or medication needs with your healthcare provider.
This heterozygous genotype is observed frequently in many populations worldwide.
Increased sleep medication association
Carrying two copies of the G allele is associated with a higher statistical probability of sleep medication purchases compared to the baseline genotype. This finding reflects a genetic association with sleep-related traits identified in large-scale GWAS research, but it does not predict individual clinical outcomes. Please consult with your doctor or pharmacist regarding any questions about your sleep health or medication requirements.
This genotype is common, though its exact frequency varies by ancestral background.
What is rs1252749?
A single nucleotide polymorphism, or SNP, is a variation at a single position in a DNA sequence among individuals. The variant rs1252749 is located in an intergenic region, meaning it sits in the DNA sequence between known protein-coding genes. Because it is not located within a gene that provides instructions for making a specific protein, its biological function is not immediately obvious. Researchers often identify such variants through genome-wide association studies (GWAS), which scan the entire genome to find statistical correlations between specific DNA locations and observable traits or behaviors. In the case of rs1252749, the variant was highlighted because individuals carrying specific alleles at this location were found to have different patterns of sleep medication purchases compared to those who did not. It is important to note that being a 'lead SNP' in a GWAS does not necessarily mean the variant itself causes the trait; it may simply be located near other functional elements that influence the biological processes involved in sleep.
Research and Evidence Strength
The association between rs1252749 and sleep medication purchases is based on large-scale epidemiological and genetic research, including studies utilizing data from the UK Biobank and the FinnGen project. These studies analyzed hundreds of thousands of individuals to identify genetic loci that correlate with the use of medications intended to manage sleep problems. While these findings provide valuable insights into the genetic architecture of sleep-related behaviors, the evidence strength for this specific variant is considered moderate. This is because GWAS findings represent statistical associations across large populations rather than direct clinical causation. Furthermore, sleep medication use is a complex trait influenced by a combination of genetic, environmental, and lifestyle factors. Current research suggests that while genetics play a role in sleep health, the purchase of medication is also heavily influenced by clinical diagnoses, psychiatric comorbidities, and individual access to healthcare. Therefore, rs1252749 should be viewed as one of many potential genetic markers rather than a definitive predictor of sleep health or medication needs.
Population Frequency
The variant rs1252749 is classified as a common variant, meaning it is found at a relatively high frequency across diverse human populations. In genetic studies, common variants are those that appear in a significant percentage of the population, often making them easier to detect in large-scale association studies. Because it is common, many individuals carry one or two copies of the variant without experiencing any specific health issues. The frequency of the alleles at this position can vary slightly depending on ancestral background, but it is generally widespread. It is important to remember that the presence of a common variant does not imply a medical condition. Most common SNPs have neutral effects on health, and their association with specific traits like medication use is often subtle, contributing only a small fraction to the overall variation observed in a population.
What You Can Do With This Information
Understanding your genetic profile regarding variants like rs1252749 can be an interesting way to learn about your biological predispositions, but it is not a substitute for professional medical advice. You cannot use this information to diagnose yourself with a sleep disorder or to determine if you need sleep medication. Genetic associations are statistical in nature and do not account for the unique clinical history, current health status, or environmental factors that a doctor considers when making treatment decisions. If you have concerns about your sleep quality or are considering the use of sleep aids, the most important step is to consult with a qualified healthcare provider or pharmacist. They can evaluate your symptoms, review your medical history, and discuss appropriate, evidence-based options for your specific needs. Never make changes to your medication regimen or health habits based solely on genetic data without first speaking to a clinician who understands your full health context.
How common is this variant?
The variant rs1252749 is a common SNP, with its alleles appearing frequently across diverse global populations.
Frequently asked questions
Does having this variant mean I have a sleep disorder?
No. This variant is associated with statistical trends in medication purchases across large populations, not with a clinical diagnosis. Sleep disorders are complex conditions that require a professional evaluation by a healthcare provider.
Can I use this SNP to predict if I will need sleep medication?
No. Genetic markers like rs1252749 provide only a very small amount of information about complex behaviors. Your actual need for medication depends on many factors, including your lifestyle, stress levels, and underlying health conditions.
Is this variant located in a gene that controls sleep?
The variant is located in an intergenic region, meaning it is not inside a known protein-coding gene. While it may be near regulatory elements that influence sleep-related processes, it does not directly code for a protein.
Should I tell my doctor about my genotype for rs1252749?
While you are free to share any information with your doctor, they generally rely on clinical symptoms and medical history to guide treatment. Genetic data from consumer tests is typically not used for clinical decision-making regarding sleep medication.
Sources & further reading
Educational information only, last refreshed 9/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1252749?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants
The rare allele of this exon-derived SNP is significantly under-represented in centenarians, suggesting a potential role in human longevity.
A candidate SNP in the adiponectin gene investigated for its potential association with human longevity and aging phenotypes.
This variant in the CYP1B1 gene is involved in metabolic pathways that may influence individual responses to environmental stressors and xenobiotics.
Functional prostanoid DP receptor promoter region polymorphism modifying transcriptional activity and associated with susceptibility to asthma and allergic inflammation.
Intronic variant within the protein kinase C alpha (PRKCA) gene significantly associated with susceptibility to childhood asthma and allergic airway hyperresponsiveness.
Regulatory variant in the PTGDR locus influencing DP receptor transcription efficiency, conferring altered risk for allergic asthma onset.